Latest News
The 2023 Helen Keller Laureates Gustavo D. Aguirre, VMD, PhD, Jean Bennett, MD, PhD, Samuel G. Jacobson, MD, PhD (posthumously), Albert M. Maguire, MD, and T. Michael Redmond, PhD, were awarded the 2023 Helen Keller Prize for Vision Research on April 25 by BrightFocus Foundation and the Helen Keller Foundation for Research and Education.
BrightFocus Foundation was honored on April 22 by the Association for Research in Vision and Ophthalmology (ARVO) in New Orleans.
BrightFocus Foundation, an international nonprofit funder of brain and vision research, recognized five leading vision scientists for their ideas to prevent, treat, and cure macular degeneration and glaucoma during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).
A BrightFocus-funded research team has some eye-opening news: They’ve used artificial intelligence to develop a model that could one day detect Alzheimer’s disease through photographs of the eye, which could lead to earlier diagnosis and treatment.
BrightFocus Foundation will support a new five-year research initiative in Canada that will study the aging brain and identify how to reduce the risks of dementia and other forms of cognitive impairment.
Register for our new Zoom in on Dementia & Alzheimer’s program, a free, monthly, virtual discussion series featuring medical experts.
BrightFocus-funded research offers the potential to restore vision loss due to glaucoma using cell replacement therapy.
Researchers have identified a new gene region in people of African descent that reduces Alzheimer's disease risk—highlighting the importance of diversity and inclusion of all populations in research.
A recent study reveals that an anti-inflammatory drug approved to treat certain autoimmune diseases can counteract a protein in the body that’s linked to age-related macular degeneration. These findings may lead to a new treatment option for the disease.
A BrightFocus Foundation-funded study found that even moderate alcohol use can cause changes in the brain that may accelerate Alzheimer’s disease, shedding new light on a possible modifiable risk factor for dementia.
